Andrew G Stephen
Overview
Explore the profile of Andrew G Stephen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
2218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Rabara D, Stephen A
Methods Mol Biol
. 2024 Apr;
2797:91-102.
PMID: 38570454
Oncogenic mutations in KRAS typically impact the GAP-mediated and intrinsic GTP hydrolysis activity resulting in elevated levels of cellular KRAS-GTP. The development of biochemical assays for GTPase activity provides an...
12.
Waybright T, Stephen A
Methods Mol Biol
. 2024 Apr;
2797:35-46.
PMID: 38570451
Biochemical and biophysical assays using recombinant RAS require the protein to be in either the active or inactive state. Here we describe methods to exchange the nucleotide present in the...
13.
Nissley D, Stephen A, Yi M, McCormick F
Methods Mol Biol
. 2024 Apr;
2797:1-12.
PMID: 38570448
RAS research has entered the world of translational and clinical science. Progress has been based on our appreciation of the role of RAS mutations in different types of cancer and...
14.
DIppolito R, Rabara D, Abreu Blanco M, Alberico E, Drew M, Ramakrishnan N, et al.
Anal Chem
. 2024 Mar;
96(13):5223-5231.
PMID: 38498381
Development of new targeted inhibitors for oncogenic KRAS mutants may benefit from insight into how a given mutation influences the accessibility of protein residues and how compounds interact with mutant...
15.
Shrestha R, Carpenter T, Van Q, Agamasu C, Tonelli M, Aydin F, et al.
Commun Biol
. 2024 Feb;
7(1):242.
PMID: 38418613
The oncogene RAS, extensively studied for decades, presents persistent gaps in understanding, hindering the development of effective therapeutic strategies due to a lack of precise details on how RAS initiates...
16.
Whitley M, Tran T, Rigby M, Yi M, Dharmaiah S, Waybright T, et al.
Sci Adv
. 2024 Feb;
10(7):eadj4137.
PMID: 38354232
, the most frequently mutated oncogene in human cancer, produces two isoforms, KRAS4a and KRAS4b, through alternative splicing. These isoforms differ in exon 4, which encodes the final 15 residues...
17.
Sharma A, Pei J, Yang Y, Dyba M, Smith B, Rabara D, et al.
J Biol Chem
. 2024 Jan;
300(2):105650.
PMID: 38237681
Individual oncogenic KRAS mutants confer distinct differences in biochemical properties and signaling for reasons that are not well understood. KRAS activity is closely coupled to protein dynamics and is regulated...
18.
Shree S, McLean M, Stephen A, Sligar S
Biochem Biophys Res Commun
. 2023 Aug;
678:122-127.
PMID: 37633182
KRas4b is a membrane-bound regulatory protein belonging to the family of small GTPases that function as a molecular switch, facilitating signal transduction from activated membrane receptors to intracellular pathways controlling...
19.
Morstein J, Shrestha R, Van Q, Lopez C, Arora N, Tonelli M, et al.
ACS Chem Biol
. 2023 Aug;
18(9):2082-2093.
PMID: 37579045
Protein-membrane interactions (PMIs) are ubiquitous in cellular signaling. Initial steps of signal transduction cascades often rely on transient and dynamic interactions with the inner plasma membrane leaflet to populate and...
20.
Yang M, Tran T, Hunt B, Agnor R, Johnson C, Shui B, et al.
Cancer Res
. 2023 Aug;
83(19):3176-3183.
PMID: 37556505
Significance: An allosteric network formed by interaction between lysine 104 and residues in the switch-II domain is required for KRAS oncogenicity, which could be exploited for developing inhibitors of the...